Max Rosett, Chief Financial Officer, on June 15, 2026, sold 60,000 shares in Immunome (IMNM) for $1,093,800. Following the Form 4 filing with the SEC, Rosett has control over a total of 54,037 common shares of the company, with 54,037 shares held directly.
SEC Filing: